Colin advises clients throughout their lifecycle (all the way from start-up/spin-out to multinational listed companies) on the commercialisation of their intellectual property rights. In particular, advising on licensing deals, collaborations and R&D projects, distribution and manufacturing and the IP, commercial and regulatory aspects of M&A, VC investments and IPOs.

Having a 1st class degree in Cell Biology his practice has naturally become focused on the life sciences, healthcare and technology (with a particular focus on med-tech and clean-tech) sectors.

Show full CV Hide full CV

Latest news & insights

Low angle view of futuristic skyscrapers
Private equity

Advising Rutland Partners on JSM Group investment

26 February 2021

by multiple authors

Click here to find out more
Genetically modified wheat growing in a petri dish
Life sciences & healthcare

Acting on transformational roll-up and $250 million crossover financing of cutting-edge UK and European biotech companies

16 February 2021

by Ross McNaughton and Colin McCall

Click here to find out more
Patterned pills
Life sciences & healthcare

Edison Open House Global Healthcare 2021 – key takeaways from our panel

4 February 2021
Quick read

by multiple authors

Click here to find out more
pipette
Synapse

Private equity investment in life sciences sector

30 July 2020
IN-DEPTH ANALYSIS

by multiple authors

Click here to find out more

Related people

Meet me at

There are no upcoming events